Tag:
Eylea
Latest Headlines
Latest Headlines
After dropping ISTA, Valeant nabs another eye-drug company
So what if Valeant Pharmaceuticals wasn't able to pull off its bid for ISTA Pharmaceuticals? It's snapping up Eyetech instead. The Canadian drugmaker ( $VRX ) agreed to pay "significantly less than two
Genentech pursues sustained-delivery version of blockbuster eye drug Lucentis
Ah, progress. Genentech has overcome an initial hurtle in its push to develop a sustained-delivery version of Lucentis , the company's blockbuster drug for age-related macular degeneration. The...
Regeneron to pay Roche royalties on Eylea sales
Genentech's spat with Regeneron Pharmaceuticals ( $REGN ) is partly settled. The two companies have been fighting over Regeneron's new injectable eye drug Eylea , which is the first challenger to
Eylea data blurs dosing advantage over Lucentis
Some new data take the edge off Bayer and Regeneron Pharmaceuticals' ( $REGN ) eye drug Eylea. Second-year results from head-to-head studies against Roche 's Lucentis found that the drugs worked equally
Regeneron finally captures an FDA OK with new eye drug
Late on Friday Regeneron Pharmaceuticals ( $REGN ) scored a big win as it announced that the FDA has approved Eylea (aflibercept) for wet, age-related macular degeneration. But after pricing an
FDA pins approval on Regeneron eye drug Eylea
Regeneron ( $REGN ) is wrapping up the week with a big victory. U.S. regulators have given market approval to the Tarrytown, NY-based company's Eylea for treating a neurovascular form of wet
